Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:43:19 Source:travelViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Yvette Fielding says her Most Haunted co
Next:Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire
You may also like
- Kevin Pillar gets 1,000th career hit in Angels' win at Texas
- Australian teen jailed for school shooting
- BBC announce Tom Hiddleston is set to return to The Night Manager for two more series
- BBC announce Tom Hiddleston is set to return to The Night Manager for two more series
- Who is Jacob Zuma, the former South African president disqualified from next week's election?
- Keanu Reeves' Good Fortune co
- Venezuelan beauty queen Wilevis Brito, 24, dies following surgery on jaw and lip
- How DO you deal with a problem like Gary Lineker?
- Company wins court ruling to continue development of Michigan factory serving EV industry